Role of interleukin‑32 in cancer progression (Review)
- Authors:
- Danyang Meng
- Hang Dong
- Chennan Wang
- Rongjia Zang
- Jianjie Wang
-
Affiliations: School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China, Department of Hematology, Shenzhen Yantian District People's Hospital, Shenzhen, Guangdong 518081, P.R. China, Department of Anesthesiology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China - Published online on: December 12, 2023 https://doi.org/10.3892/ol.2023.14187
- Article Number: 54
This article is mentioned in:
Abstract
 |
|
Dahl CA, Schall RP, He HL and Cairns JS: Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 148:597–603. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH, Han SY, Azam T, Yoon DY and Dinarello CA: Interleukin-32: A cytokine and inducer of TNFalpha. Immunity. 22:131–142. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ko NY, Mun SH, Lee SH, Kim JW, Kim DK, Kim HS, Her E, Kim SH, Won HS, Shin HS, et al: Interleukin-32α production is regulated by MyD88-dependent and independent pathways in IL-1β-stimulated human alveolar epithelial cells. Immunobiology. 216:32–40. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, et al: IL-32 promotes angiogenesis. J Immunol. 192:589–602. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S and Izuhara K: Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol. 18:233–240. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH and Park MH: Interleukin 32, inflammation and cancer. Pharmacol Ther. 174:127–137. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, et al: Interleukin-32: A new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology. 53:1819–1829. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
de Albuquerque R, Komsi E, Starskaia I, Ullah U and Lahesmaa R: The role of interleukin-32 in autoimmunity. Scand J Immunol. 93:e130122021. View Article : Google Scholar : PubMed/NCBI | |
|
Nam SY, Jeong HJ and Kim HM: Kaempferol impedes IL-32-induced monocyte-macrophage differentiation. Chem Biol Interact. 274:107–115. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Ogawa E, Kinose D, Haruna A, Takahashi T, Tanabe N, Marumo S, Hoshino Y, Hirai T, Sakai H, et al: Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells. Respir Res. 13:192012. View Article : Google Scholar : PubMed/NCBI | |
|
Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C and Chiocchia G: Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw. 16:289–292. 2005.PubMed/NCBI | |
|
Barksby HE, Nile CJ, Jaedicke KM, Taylor JJ and Preshaw PM: Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide. Clin Exp Immunol. 156:479–487. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jeong HJ, Shin SY, Oh HA, Kim MH, Cho JS and Kim HM: IL-32 up-regulation is associated with inflammatory cytokine production in allergic rhinitis. J Pathol. 224:553–563. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kang YH, Park MY, Yoon DY, Han SR, Lee CI, Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, et al: Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. Cancer Lett. 318:226–233. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS, Kim SH, Han JY and Yoon DY: A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology. 128 (1 Suppl):e532–e540. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dinarello CA and Kim SH: IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis. 65 (Suppl 3):iii61–iii64. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Wang S, Su J, Chu G, You H, Chen Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther. 9:4225–4237. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA and Kim SH: Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA. 103:3316–3321. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heinhuis B, Netea MG, van den Berg WB, Dinarello CA and Joosten LAB: Interleukin-32: A predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 60:321–327. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pendergraft WF III, Rudolph EH, Falk RJ, Jahn JE, Grimmler M, Hengst L, Jennette JC and Preston GA: Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int. 65:75–84. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ and Preston GA: Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol. 15:2103–2114. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon OC, Ghang B, Lee EJ, Hong S, Lee CK, Yoo B, Kim S and Kim YG: Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus. Int J Rheum Dis. 22:1305–1311. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue M, Shoda H, Seri Y, Kubo K, Kanda H, Fujio K and Yamamoto K: Three cases of lupus nephritis patients with serum interleukin-32γ detection. Lupus. 23:1187–1191. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Caramori G, Adcock IM, Di Stefano A and Chung KF: Cytokine inhibition in the treatment of COPD. nt J Chron Obstruct Pulmon Dis. 9:397–412. 2014.PubMed/NCBI | |
|
Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA and Joosten LAB: Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 287:5733–5743. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Park MH, Yoon DY, Ban JO, Kim DH, Lee DH, Song S, Kim Y, Han SB, Lee HP and Hong JT: Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32β overexpressed transgenic mice. Oncotarget. 6:38566–38577. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dos Santos JC, Heinhuis B, Gomes RS, Damen MS, Real F, Mortara RA, Keating ST, Dinarello CA, Joosten LA and Ribeiro-Dias F: Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species. PLoS Negl Trop Dis. 11:e00054132017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Zhang S, Pan X, Cao H, Huang X, Xu Q, Zhong H and Peng X: TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway. Int Immunopharmacol. 38:233–237. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA and Kim SH: Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA. 105:3515–3520. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA and Kim SH: IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA. 102:16309–16314. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Becker S, Warren MK and Haskill S: Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J Immunol. 139:3703–3709. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Delneste Y, Charbonnier P, Herbault N, Magistrelli G, Caron G, Bonnefoy JY and Jeannin P: Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood. 101:143–150. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lo AS, Gorak-Stolinska P, Bachy V, Ibrahim MA, Kemeny DM and Maher J: Modulation of dendritic cell differentiation by colony-stimulating factor-1: Role of phosphatidylinositol 3′-kinase and delayed caspase activation. J Leukoc Biol. 82:1446–1454. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM and Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med. 180:83–93. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 179:1109–1118. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Chomarat P, Banchereau J, Davoust J and Palucka AK: IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 1:510–514. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gorvel L, Korenfeld D, Tung T and Klechevsky E: Dendritic cell-derived IL-32α: A novel inhibitory cytokine of NK cell function. J Immunol. 199:1290–1300. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Borzouei S, Gholamian-Hamadan M and Behzad M: Impact of interleukin-32α on T helper cell-related cytokines, transcription factors, and proliferation in patients with type 2 diabetes mellitus. Immunopharmacol Immunotoxicol. 45:268–276. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Di Sabatino A, Giuffrida P, Fornasa G, Salvatore C, Vanoli A, Naviglio S, De Leo L, Pasini A, De Amici M, Alvisi C, et al: Innate and adaptive immunity in self-reported nonceliac gluten sensitivity versus celiac disease. Dig Liver Dis. 48:745–752. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park YS, Kang JW, Lee DH, Kim MS, Bak Y, Yang Y, Lee HG, Hong J and Yoon DY: Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification. Oncotarget. 5:8765–8777. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, Ban JO, Kang JW, Lee DH, Shim JH, et al: IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene. 30:3345–3359. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS, Han SB, Ham HJ, Park JH, Lee JS, Hwang DY, Jung YS, Yoon DY and Hong JT: IL-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B. J Allergy Clin Immunol. 146:156–168. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wallimann A and Schenk M: IL-32 as a potential biomarker and therapeutic target in skin inflammation. Front Immunol. 14:12642362023. View Article : Google Scholar : PubMed/NCBI | |
|
Park MH, Song MJ, Cho MC, Moon DC, Yoon DY, Han SB and Hong JT: Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Mmunology. 135:63–72. 2012. | |
|
Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, Lee DH, Kang JW, Park YH, Yu D, et al: Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death Dis. 4:e6402013. View Article : Google Scholar : PubMed/NCBI | |
|
Jung YY, Katila N, Neupane S, Shadfar S, Ojha U, Bhurtel S, Srivastav S, Son DJ, Park PH, Yoon DY, et al: Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32β transgenic mice. Neurochem Int. 102:79–88. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ni X, Zhang X, Hu CH, Langridge T, Tarapore RS, Allen JE, Oster W and Duvic M: ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways. Oncotarget. 8:61761–61776. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin X, Yang L, Wang G, Zi F, Yan H, Guo X, Chen J, Chen Q, Huang X, Li Y, et al: Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells. Oncotarget. 8:92841–92854. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hussain SP and Harris CC: Inflammation and cancer: An ancient link with novel potentials. Int J Cancer. 121:2373–2380. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ting WC, Chen LM, Huang LC, Hour MJ, Lan YH, Lee HZ, You BJ, Chang TY and Bao BY: Impact of interleukin-10 gene polymorphisms on survival in patients with colorectal cancer. J Korean Med Sci. 28:1302–1306. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M and Salifoglou A: Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γ. PLoS One. 8:e736162013. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, et al: Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 6:1806–1816. 2013.PubMed/NCBI | |
|
Yang Y, Wang Z, Zhou Y, Wang X, Xiang J and Chen Z: Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol. 13:1462015. View Article : Google Scholar : PubMed/NCBI | |
|
Yun HM, Park KR, Kim EC, Han SB, Yoon DY and Hong JT: IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget. 6:9061–9072. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ebach DR, Newberry R and Stenson WF: Differential role of tumor necrosis factor receptors in TNBS colitis. Inflamm Bowel Dis. 11:533–540. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, Kim JH, Kim EJ, Park DK, Kim SH, et al: Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol. 18:1606–1612. 2008.PubMed/NCBI | |
|
Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH and Lin KH: Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res. 20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ishigami S, Arigami T, Uchikado Y, Setoyama T, Kita Y, Sasaki K, Okumura H, Kurahara H, Kijima Y, Harada A, et al: IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol. 30:4722013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Chen F and Tang L: IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett. 9:305–307. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Xu R, Hu L, You J, Jiang N, Li C, Che C, Wang Q, Xu Q and Li J: Interleukin-32 induced thymic stromal lymphopoietin plays a critical role in the inflammatory response in human corneal epithelium. Cell Signal. 49:39–45. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nicholl MB, Chen X, Qin C, Bai Q, Zhu Z, Davis MR and Fang Y: IL-32α has differential effects on proliferation and apoptosis of human melanoma cell lines. J Surg Oncol. 113:364–369. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park HM, Park JY, Kim NY, Kim J, Pham TH, Hong JT and Yoon DY: Modulatory effects of point-mutated IL-32θ (A94V) on tumor progression in triple-negative breast cancer cells. Biofactors. Sep 2–2023.(Epub ahead of print). View Article : Google Scholar | |
|
Pham TH, Bak Y, Kwon T, Kwon SB, Oh JW, Park JH, Choi YK, Hong JT and Yoon DY: Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer. Cell Commun Signal. 17:532019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS, Kim KC, Mongre RK, Kim JY, Kim YR, Choi DY, Song S, Yun J, Han SB, Yoon DY and Hong JT: IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway. Cell Death Dis. 10:5062019. View Article : Google Scholar : PubMed/NCBI | |
|
Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S, Ciampoli C, et al: IL-32: A newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents. 23:141–147. 2009.PubMed/NCBI | |
|
Ma Z, Dong Z, Yu D, Mu M, Feng W, Guo J, Cheng B, Guo J and Ma J: IL-32 promotes the radiosensitivity of esophageal squamous cell carcinoma cell through STAT3 pathway. Biomed Res Int. 2021:66537472021.PubMed/NCBI | |
|
Sorrentino C and Di Carlo E: Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 180:769–779. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yun J, Park MH, Son DJ, Nam KT, Moon DB, Ju JH, Hwang OK, Choi JS, Kim TH, Hwang DY, et al: IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. Cell Death Dis. 9:3062018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Pan X, Cao H, Shu X, Sun H, Lu J, Liang J, Zhang K, Zhu F, Li G and Zhang Q: IL-32γ promotes integrin αvβ6 expression through the activation of NF-κB in HSCs. Exp Ther Med. 14:3880–3886. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Yang Y, Zhu Y, Li L, Chen F and Zhang L: Polymorphisms and expression of IL-32: Impact on genetic susceptibility and clinical outcome of lung cancer. Biomarkers. 22:165–170. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zou Y, Bao J, Pan X, Lu Y, Liao S, Wang X, Wang G and Lin D: NKP30-B7-H6 interaction aggravates hepatocyte damage through up-regulation of interleukin-32 expression in hepatitis b virus-related acute-on-chronic liver failure. PLoS One. 10:e01345682015. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida A, Andoh A, Inatomi O and Fujiyama Y: Interleukin-32 expression in the pancreas. J Biol Chem. 284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yousif NG, Al-Amran FG, Hadi N, Lee J and Adrienne J: Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 61:223–227. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Takagi K, Imura J, Shimomura A, Noguchi A, Minamisaka T, Tanaka S, Nishida T, Hatta H and Nakajima T: Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32. Oncol Lett. 20:2888–2896. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cai A, Qi S, Su Z, Shen H, Ma W and Dai Y: Tripterygium glycosides inhibit inflammatory mediators in the rat synovial RSC-364 cell line stimulated with interleukin-1β. Biomed Rep. 3:763–766. 2015. View Article : Google Scholar : PubMed/NCBI |
